Date: 2012-05-02
Type of information: Fundraising
Company: Galecto Biotech (Sweden)
Investors: Sunstone Capital (Denmark) - SEED Capital (Denmark)
Amount:
Funding type: financing round
Planned used: The additional funding will enable the company to accelerate development of its key drug candidates.
Others: Galecto Biotech ’s first financing round has been expanded and that two new investors, SEED Capital and Sunstone Capital, will join Novo A/S and Merck Serono Ventures in the company’s investor syndicate. The company will use the proceeds to advance its unique galectin modulators, which have the potential to treat a range of life threatening diseases. The first financing round has been intiated in January (See http://biopharmanalyses.fr/fundraising-and-ipo/?pageid=250).
Therapeutic area: Inflammatory diseases - Fibrosis
